Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Public-Private Consortium To Strengthen Essential Medicines Supply Under White House Initiative

Executive Summary

President Biden’s 100-day plan relies on Defense Production Act authorities to increase resilience of critical domestic pharmaceutical supplies.

You may also be interested in...



Medicare Floats Essential Medicine ‘Buffer Stock’ Incentive For Hospitals

The US is proposing to pay hospitals extra to maintain reserve supplies of ‘essential medicines’ to help mitigate shortages. But would the plan only make the problem worse?

Drug Shortages Back In US Congressional Spotlight

Drug shortages were a significant focus of legislative attention in the US before the COVID-19 pandemic, and Congress is not likely to drop the issue now that the public health emergency is winding down.

China Rhetoric Could Be Key To US FDA IT System Upgrade

FDA Commissioner Robert Califf says mentioning China helps increase congressional support.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS144447

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel